We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.82B Turnover 23.39%
1-Year Est. Return 53.85%
 

Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.

This Fund
S&P 500
This Quarter Est. Return
-10.66%
1 Year Est. Return
+53.85%
3 Year Est. Return
+187.03%
5 Year Est. Return
+202.92%
10 Year Est. Return
+987.38%
AUM
$551M
AUM Growth
–
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
31.05%
Holding
130
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Financials 1.6%
3 Miscellaneous 1.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
GILD icon
1
Gilead Sciences
GILD
$206B
$21.4M 3.89%
233,300
– –
2016 Q1
0 quarters
CELG
2
DELISTED
Celgene
CELG
$21.1M 3.82%
210,550
– –
2016 Q1
0 quarters
MDT icon
3
Medtronic
MDT
$128B
$20.7M 3.76%
276,500
– –
2016 Q1
0 quarters
BIIB icon
4
Biogen
BIIB
$36.9B
$19.9M 3.62%
76,540
– –
2016 Q1
0 quarters
ABT icon
5
Abbott
ABT
$178B
$16M 2.9%
381,500
– –
2016 Q1
0 quarters
AMGN icon
6
Amgen
AMGN
$236B
$15.4M 2.8%
103,000
– –
2016 Q1
0 quarters
BDX icon
7
Becton Dickinson
BDX
$58B
$15.2M 2.76%
100,225
– –
2016 Q1
0 quarters
ILMN icon
8
Illumina
ILMN
$29.2B
$14.9M 2.7%
91,625
– –
2016 Q1
0 quarters
SYK icon
9
Stryker
SYK
$118B
$13.4M 2.43%
125,000
– –
2016 Q1
0 quarters
CAH icon
10
Cardinal Health
CAH
$63.1B
$13.1M 2.37%
159,630
– –
2016 Q1
0 quarters
UNH icon
11
UnitedHealth
UNH
$305B
$12M 2.18%
93,000
– –
2016 Q1
0 quarters
REGN icon
12
Regeneron Pharmaceuticals
REGN
$95.2B
$11.7M 2.12%
32,400
– –
2016 Q1
0 quarters
TEVA icon
13
Teva Pharmaceutical Industries
TEVA
$45.8B
$10.4M 1.9%
195,290
– –
2016 Q1
0 quarters
VTRS icon
14
Viatris
VTRS
$22.5B
$10.2M 1.85%
220,000
– –
2016 Q1
0 quarters
BSX icon
15
Boston Scientific
BSX
$60.8B
$9.4M 1.71%
500,000
– –
2016 Q1
0 quarters
ZBH icon
16
Zimmer Biomet
ZBH
$19.1B
$9.19M 1.67%
86,200
– –
2016 Q1
0 quarters
CVS icon
17
CVS Health
CVS
$103B
$8.94M 1.62%
86,200
– –
2016 Q1
0 quarters
LGND icon
18
Ligand Pharmaceuticals
LGND
$5.74B
$8.76M 1.59%
81,830
– –
2016 Q1
0 quarters
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$14.8B
$8.16M 1.48%
62,500
– –
2016 Q1
0 quarters
CYTO icon
20
DELISTED
Altamira Therapeutics Ltd
CYTO
$7.9M 1.43%
27
– –
2016 Q1
0 quarters
ISRG icon
21
Intuitive Surgical
ISRG
$138B
$7.81M 1.42%
117,000
– –
2016 Q1
0 quarters
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$6.88M 1.25%
49,400
– –
2016 Q1
0 quarters
MCK icon
23
McKesson
MCK
$123B
$6.76M 1.23%
43,000
– –
2016 Q1
0 quarters
SUPN icon
24
DELISTED
Supernus Pharmaceuticals
SUPN
$6.72M 1.22%
441,000
– –
2016 Q1
0 quarters
STJ
25
DELISTED
St. Jude Medical
STJ
$6.71M 1.22%
122,000
– –
2016 Q1
0 quarters

Similar funds

Bellevue Group's Q1 2016 Portfolio in Review

Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.

Its largest position is Gilead Sciences: 233,300 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, followed by Financials and Miscellaneous.

  • Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
  • Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.

Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.